BioCentury
ARTICLE | Clinical News

ISIS-APO: Phase I/IIa data

November 16, 2015 8:00 AM UTC

A double-blind, placebo-controlled Phase I/IIa trial in 50 patients with elevated LPA levels showed that single subcutaneous doses of ISIS-APO(a)-LRx led to mean and maximum reductions in LPA levels a...